OncoMatch/Clinical Trials/NCT07249346
Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
Is NCT07249346 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Ruxolitinib and Myeloablative conditioning regimen for leukemia.
Treatment: Ruxolitinib · Myeloablative conditioning regimen · Cyclophosphamide · Tacrolimus — This is an open label, non-randomized, multicenter, pilot, dose expansion study of low dose post-transplant cyclophosphamide (25 mg/kg on Days +3 and +4)/tacrolimus/ruxolitinib in the setting of myeloablative conditioning (MAC) allogeneic peripheral blood stem cell transplantation (PBSCT).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Chemotherapy
Other
Cancer type
Acute Myeloid Leukemia
Prior therapy
Must have received: myeloablative conditioning regimen — planned
Planned myeloablative (MAC) conditioning regimen
Cannot have received: allogeneic transplant
Prior allogeneic transplant
Cannot have received: ruxolitinib (ruxolitinib)
Prior use of ruxolitinib
Cannot have received: immune checkpoint inhibitor
Prior use of immune checkpoint inhibitors (i.e., PD1, PDL1, CTLA4 modulators) within six (6) months prior to conditioning
Lab requirements
Kidney function
Estimated creatinine clearance >60 ml/min (C-G formula)
Liver function
AST/ALT <3x ULN; Total bilirubin <2 mg/dL excluding Gilbert's syndrome or hemolysis
Cardiac function
Left ventricular ejection fraction at least 45%
Cardiac function: Left ventricular ejection fraction at least 45%; Estimated creatinine clearance greater than 60 ml/min (C-G formula); Liver function: AST/ALT <3x ULN; Total bilirubin <2 mg/dL excluding Gilbert's syndrome or hemolysis; There are no restrictions based on blood counts
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Ohio State University Comprehensive Cancer Center · Columbus, Ohio
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07249346 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior allogeneic transplant, ruxolitinib, immune checkpoint inhibitor disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages